259 related articles for article (PubMed ID: 31488153)
21. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
22. Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.
Keller L; Guibert N; Casanova A; Brayer S; Farella M; Delaunay M; Gilhodes J; Martin E; Balagué G; Favre G; Pradines A; Meyer N
Acta Derm Venereol; 2019 Feb; 99(2):206-210. PubMed ID: 30393817
[TBL] [Abstract][Full Text] [Related]
23. Use of circulating tumoral DNA to guide treatment for metastatic melanoma.
Herbreteau G; Charpentier S; Vallée A; Denis MG
Pharmacogenomics; 2019 Dec; 20(18):1259-1270. PubMed ID: 31596166
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal Relationship between Idylla Plasma ctBRAF V600 Mutation Detection and Tumor Burden in Patients with Metastatic Melanoma.
Linder MW; Egger ME; Van Meter T; Rai SN; Valdes R; Hall MB; Wu X; Alghamdi N; Chesney JA
Mol Diagn Ther; 2021 May; 25(3):361-371. PubMed ID: 33970440
[TBL] [Abstract][Full Text] [Related]
25. Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression.
Marsavela G; McEvoy AC; Pereira MR; Reid AL; Al-Ogaili Z; Warburton L; Khattak MA; Abed A; Meniawy TM; Millward M; Ziman MR; Calapre L; Gray ES
Br J Cancer; 2022 Feb; 126(3):401-408. PubMed ID: 34373567
[TBL] [Abstract][Full Text] [Related]
26. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
J Cancer Res Clin Oncol; 2019 Feb; 145(2):511-521. PubMed ID: 30539281
[TBL] [Abstract][Full Text] [Related]
27. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.
Seban RD; Nemer JS; Marabelle A; Yeh R; Deutsch E; Ammari S; Moya-Plana A; Mokrane FZ; Gartrell RD; Finkel G; Barker L; Bigorgne AE; Schwartz LH; Saenger Y; Robert C; Dercle L
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2298-2310. PubMed ID: 31346755
[TBL] [Abstract][Full Text] [Related]
28. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML
JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901
[TBL] [Abstract][Full Text] [Related]
29. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
30. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients.
Marczynski GT; Laus AC; Dos Reis MB; Reis RM; Vazquez VL
Sci Rep; 2020 Oct; 10(1):18682. PubMed ID: 33122747
[TBL] [Abstract][Full Text] [Related]
32. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
33. Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer.
Ma F; Guan Y; Yi Z; Chang L; Li Q; Chen S; Zhu W; Guan X; Li C; Qian H; Xia X; Yang L; Zhang J; Husain H; Liao Z; Futreal A; Huang J; Yi X; Xu B
Int J Cancer; 2020 Mar; 146(5):1359-1368. PubMed ID: 31241775
[TBL] [Abstract][Full Text] [Related]
34. Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.
Lee JH; Saw RP; Thompson JF; Lo S; Spillane AJ; Shannon KF; Stretch JR; Howle J; Menzies AM; Carlino MS; Kefford RF; Long GV; Scolyer RA; Rizos H
Ann Oncol; 2019 May; 30(5):815-822. PubMed ID: 30860590
[TBL] [Abstract][Full Text] [Related]
35. Microarray-based analysis of the BRAF V600 mutations in circulating tumor DNA in melanoma patients.
Emelyanova MA; Telysheva EN; Orlova KV; Ryabaya OO; Snigiryova GP; Abramov IS; Mikhailovich VM
Cancer Genet; 2021 Jan; 250-251():25-35. PubMed ID: 33249369
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis.
Zheng Y; Sun H; Cong L; Liu C; Sun Q; Wu N; Cong X
J Oncol; 2021; 2021():6660571. PubMed ID: 34035810
[TBL] [Abstract][Full Text] [Related]
37. Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol.
Geoffrois L; Harlé A; Sahki N; Sikanja A; Granel-Brocard F; Hervieu A; Mortier L; Jeudy G; Michel C; Nardin C; Huin-Schohn C; Merlin JL
BMC Cancer; 2023 Jun; 23(1):554. PubMed ID: 37328818
[TBL] [Abstract][Full Text] [Related]
38. Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.
Garlan F; Blanchet B; Kramkimel N; Puszkiel A; Golmard JL; Noe G; Dupin N; Laurent-Puig P; Vidal M; Taly V; Thomas-Schoemann A
Target Oncol; 2017 Jun; 12(3):365-371. PubMed ID: 28527094
[TBL] [Abstract][Full Text] [Related]
39. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.
Czarnecka AM; Teterycz P; Mariuk-Jarema A; Lugowska I; Rogala P; Dudzisz-Sledz M; Switaj T; Rutkowski P
Target Oncol; 2019 Dec; 14(6):729-742. PubMed ID: 31754963
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline.
Knol AC; Vallée A; Herbreteau G; Nguyen JM; Varey E; Gaultier A; Théoleyre S; Saint-Jean M; Peuvrel L; Brocard A; Quéreux G; Khammari A; Denis MG; Dréno B
Exp Dermatol; 2016 Oct; 25(10):783-8. PubMed ID: 27194447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
